

## Confirmed Speakers

### Confirmed Speakers

#### Ehrlich Prize Winner

##### Natural Antitumor Macrolides Acting on Tubulin: Synthesis and Functional Exploration



Prof. Karl-Heinz ALTMANN  
(SCS DMCCB & SWISS FEDERAL INSTITUTE OF TECHNOLOGY, Zürich, Switzerland)

##### PDE10A Inhibitors as Potential Treatments for Schizophrenia



Dr Jose Manuel BARTOLOME  
(JANSSEN RESEARCH & DEVELOPMENT, Toledo, Spain)

##### Recent Advances in Predicting Cardiac Risk during Drug Development



Dr Arthur BROWN  
(CHANTEST, Cleveland, United States)

##### Excursions in Uncharted Structural Space



Prof. Erick M. CARREIRA  
(ETH ZÜRICH, Zürich, Switzerland)

##### Novel Imidazoles as Selective TAAR1 Partial Agonists for the Treatment of Psychiatric Disorders



Dr Giuseppe CECERE  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

##### Exploiting the Information Rich Output of SPR Biosensor Technology in Drug Discovery – From Target Evaluation to Fragment and Lead



Prof. Helena DANIELSON  
(UPPSALA UNIVERSITY, Uppsala, Sweden)

##### Translational Biophysics: Using Biophysical Data in Medicinal Chemistry



Dr Matthias FRECH  
(MERCK, Darmstadt, Germany)

##### Use of Peptides to Modulate Protein-Protein Interactions



Prof. Ernest GIRALT  
(INSTITUTE FOR RESEARCH IN BIOMEDICINE (IRB), Barcelona, Spain)

##### Discovery and Optimisation of a Novel Series of EZH2 Inhibitors, Challenges and Clinical Perspectives

## Confirmed Speakers



Dr Jean-Christophe HARMANGE  
(CONSTELLATION PHARMACEUTICALS, Cambridge, United States)

### **Molecular Basis of Ligand Dissociation from GPCRs – a Molecular Dynamics and Mutagenesis Study on the Adenosine A<sub>2A</sub> Receptor**



Dr Laura HEITMAN  
(UNIVERSITY OF LEIDEN, Leiden, The Netherlands)

### **The Design and Optimisation of Selective Protein Kinase C Theta Inhibitors for the Treatment of Autoimmune Diseases**



Dr Juan-Miguel JIMENEZ  
(VERTEX PHARMACEUTICALS, Abingdon, United Kingdom)

### **Cell Identity Loss in Cancer: a Source of New Biomarkers and Therapeutic Targets**



Dr Saadi KHOCHBIN  
(JOSEPH FOURIER UNIVERSITY, Grenoble, France)

### **The Lab Oddity Prevails - Discovery of pan-CDK Inhibitor BAY 1000394 (Roniciclib) for the Treatment of Cancer**



Dr Ulrich LÜCKING  
(BAYER HEALTHCARE, Basel, Switzerland)

### **Targeting BAX for Cancer Therapy: from Computer Screen to Mouse**



Dr Luciana MARINELLI  
(UNIVERSITY OF NAPOLI, Napoli, Italy)

### **Polar Units and Dipolar Interactions Modulating, Conformation, Lipophilicity, and other Physicochemical Properties**



Prof. Klaus MÜLLER  
(F. HOFFMANN-LA ROCHE, Switzerland)

### **Specific Antidotes for Dabigatran: Structure-Guided Affinity Optimisation and Functional Characterisation**



Dr Herbert NAR  
(BOEHRINGER INGELHEIM, Biberach, Germany)

### **High-Throughput Chemical Microarray SPR: The Biophysical Tool for Fragment Based Screening in Drug Discovery**

## Confirmed Speakers



Dr Thomas NEUMANN  
(GRAFFINITY PHARMACEUTICALS, Illkirch, France)

### Discovery of TAK-632: Pan-RAF Inhibitor with Potent Antitumor Activity against *BRAF* and *NRAS* Mutant Melanomas



Dr Masanori OKANIWA  
(TAKEDA PHARMACEUTICAL COMPANY, Kanagawa, Japan)

### Chemical Probes for Epigenetics



Dr Dafydd OWEN  
(PFIZER, Cambridge, United States)

### Design and Applications of Protein Epitope Mimetics



Prof. John ROBINSON  
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

### Pseudo-Natural Product Synthesis and Drug Applications



Prof. Hiroaki SUGA  
(UNIVERSITY OF TOKYO, Tokyo, Japan)

### 2-Clips Peptides: A Novel Class of Biopharmaceuticals



Prof. Peter TIMMERMAN  
(PEPSCAN THERAPEUTICS, Lelystad, The Netherlands)

### Genotoxicity Screening can guide Lead Optimisation and Reduce Late Stage Attrition



Prof. Richard WALMSLEY  
(UNIVERSITY OF MANCHESTER, Manchester, United Kingdom)

### Strategies to Target Protein-Protein Interactions: from Discovery to Clinical Development



Prof. Shaomeng WANG  
(UNIVERSITY OF MICHIGAN, Michigan, United States)

## Short Communications

### Identification of Cell-penetrating Compounds and their Use for Intracellular Delivery of Cathepsin D Inhibitors

## Confirmed Speakers



Prof. Muriel AMBLARD  
(CNRS-UNIVERSITY OF MONTPELLIER I, Montpellier, France)

### **Silicon-containing Tetrahydrocyclopenta[c]acridine Derivatives as CDKs Inhibitors: Design, Organometallic Synthesis, Metabolic Stability and Optimisation**



Prof. Philippe BELMONT  
(UNIVERSITY PARIS DESCARTES, Paris, France)

### **Innovative Fluorescent-Based Approaches to GPCR Screening and Functional Architecture Studies**



Prof. Dominique BONNET  
(UNIVERSITY OF STRASBOURG, Illkirch, France)

### **Combining Organic Synthesis, Software Development and Biochemistry for the Design and Discovery of Prolyl oligopeptidase Inhibitors**



Prof. Nicolas MOITESSIER  
(MCGILL UNIVERSITY, Montreal, Canada)